Skip to main content

UNITED THERAPEUTICS Corp

For the period ended Jun 30, 2025. Filed Jul 30, 2025.

View on SEC.gov

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Jun 30, 2025 · Filed Jul 30, 2025

UTHR$582.46+3.6%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Consolidated Balance Sheets

(In millions, except share and per share data)

June 30, 2025December 31, 2024
(Unaudited)
Assets
Current assets:
Cash and cash equivalents$1,593.1$1,697.2
Marketable investments1,455.61,569.8
Accounts receivable, no allowance for 2025 and 2024379.3279.3
Inventories, net169.2157.9
Other current assets229.7169.7
Total current assets3,826.93,873.9
Marketable investments1,917.71,475.3
Goodwill and other intangible assets, net111.5111.9
Property, plant, and equipment, net1,362.41,222.4
Deferred tax assets, net456.2458.4
Other non-current assets233.3222.1
Total assets$7,908.0$7,364.0
Liabilities and Stockholders’ Equity
Current liabilities:
Accounts payable and accrued expenses$432.0$344.5
Line of credit—300.0
Other current liabilities95.193.6
Total current liabilities527.1738.1
Other non-current liabilities207.3181.9
Total liabilities734.4920.0
Commitments and contingencies
Stockholders’ equity:
Preferred stock, par value $.01, 10,000,000 shares authorized, no shares issued——
Common stock, par value $.01, 245,000,000 shares authorized, 75,381,852 and 74,997,896 shares issued, and 45,215,262 and 44,831,306 shares outstanding as of June 30, 2025 and December 31, 2024, respectively0.80.8
Additional paid-in capital2,793.42,698.9
Accumulated other comprehensive loss—(3.4)
Treasury stock, 30,166,590 shares as of June 30, 2025 and December 31, 2024, respectively(3,474.5)(3,474.5)
Retained earnings7,853.97,222.2
Total stockholders’ equity7,173.66,444.0
Total liabilities and stockholders’ equity$7,908.0$7,364.0
Quarterly Report3
ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.